Approval Year
| Substance Class |
Protein
Created
by
admin
on
Edited
Sat Dec 16 12:11:29 UTC 2023
by
admin
on
Sat Dec 16 12:11:29 UTC 2023
|
| Protein Sub Type | |
| Sequence Type | COMPLETE |
| Record UNII |
AL17N8ZSWL
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
AL17N8ZSWL
Created by
admin on Sat Dec 16 12:11:32 UTC 2023 , Edited by admin on Sat Dec 16 12:11:32 UTC 2023
|
PRIMARY | |||
|
P37231
Created by
admin on Sat Dec 16 12:11:32 UTC 2023 , Edited by admin on Sat Dec 16 12:11:32 UTC 2023
|
PRIMARY | |||
|
PEROXISOME_PROLIFERATOR-ACTIVATED_RECEPTOR_GAMMA
Created by
admin on Sat Dec 16 12:11:32 UTC 2023 , Edited by admin on Sat Dec 16 12:11:32 UTC 2023
|
PRIMARY |
| Linkage Type | Residue Index | |||
|---|---|---|---|---|
| COORDINATION COMPOUND | 1_139 | 1_142 | 1_156 | 1_159 |
| COORDINATION COMPOUND | 1_176 | 1_180 | 1_190 | 1_193 |
| Glycosylation Type | HUMAN |
| Glycosylation Link Type | Site |
|---|---|
| O | 1_84 |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
AGONIST -> TARGET | |||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Binding Assay
IC50
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
Binding Assay
IC50
|
||
|
INHIBITOR -> TARGET |
|
||
|
PARTIAL AGONIST->TARGET |
In a cell-based reporter assay designed to detect full agonist activity, INT131 activates PPARγ with an efficacy of only about 10% of that of rosiglitazone.
BINDING
Ki
|
||
|
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET | |||
|
WEAK AGONIST->TARGET |
|
||
|
|
PARTIAL AGONIST->TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
|
ACTIVATOR -> TARGET | |||
|
AGONIST -> TARGET |
Tesaglitazar is a novel dual-acting peroxisome proliferator-activated receptor alpha and gamma agonist.
|
||
|
AGONIST -> TARGET |
|
||
|
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Ki=4.7 micromolar (Supplementary Fig. S5; http://clincancerres.aacrjournals.org/content/22/10/2508.figures-only)
IN-VITRO
IC50
|
||
|
|
INHIBITOR -> TARGET | |||
|
AGONIST -> TARGET |
sarogli tazar has a predominant affinity for the PPAR-α isoform, and an intermediate affinity for PPAR-γ
|
||
|
AGONIST -> TARGET |
|
||
|
INHIBITOR -> TARGET |
IC50
|
||
|
|
AGONIST -> TARGET | |||
|
PARTIAL AGONIST->TARGET |
|
||
|
|
AGONIST -> TARGET | |||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
Binding Assay
IC50
|
||
|
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
||
|
AGONIST -> TARGET |
|
| Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
|---|---|---|---|---|---|---|
| MOL_WEIGHT | CHEMICAL |
|